These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 12364434

  • 21. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 25. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
    Stewart PM, Stewart SE, Clark PM, Sheppard MC.
    Clin Endocrinol (Oxf); 1999 Mar 12; 50(3):295-9. PubMed ID: 10435053
    [Abstract] [Full Text] [Related]

  • 26. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.
    Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P.
    Endocr J; 2007 Jun 12; 54(3):459-64. PubMed ID: 17495423
    [Abstract] [Full Text] [Related]

  • 27. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.
    Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G.
    J Clin Endocrinol Metab; 2008 Sep 12; 93(9):3436-42. PubMed ID: 18593770
    [Abstract] [Full Text] [Related]

  • 28. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G.
    J Clin Endocrinol Metab; 2006 Jun 12; 91(6):2112-8. PubMed ID: 16537687
    [Abstract] [Full Text] [Related]

  • 29. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May 12; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D.
    Eur J Endocrinol; 2004 Sep 12; 151(3):317-24. PubMed ID: 15362960
    [Abstract] [Full Text] [Related]

  • 31. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
    Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB.
    Pituitary; 2004 Sep 12; 7(3):139-144. PubMed ID: 16328564
    [Abstract] [Full Text] [Related]

  • 32. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan 12; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 33. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
    Gołkowski F, Buziak-Bereza M, Huszno B.
    Przegl Lek; 2006 Jan 12; 63(3):117-22. PubMed ID: 16967698
    [Abstract] [Full Text] [Related]

  • 34. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R.
    J Clin Endocrinol Metab; 2003 Nov 12; 88(11):5258-65. PubMed ID: 14602759
    [Abstract] [Full Text] [Related]

  • 35. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM.
    Clin Endocrinol (Oxf); 2000 Nov 12; 53(5):577-86. PubMed ID: 11106918
    [Abstract] [Full Text] [Related]

  • 36. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.
    Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE.
    Pituitary; 2003 Nov 12; 6(1):11-8. PubMed ID: 14674719
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar 12; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 39. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov 12; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 40. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J, Rabijewski M, Zgliczyński W.
    Endokrynol Pol; 2005 Nov 12; 56(6):862-70. PubMed ID: 16821203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.